Search

everythinglearnresearchcommunity

for

Search:↓

More research is needed to understand alopecia areata severity.

Alopecia areata, a type of hair loss, is likely an autoimmune disease with a genetic link, but its exact cause is still unknown.

People with alopecia areata have higher rates of mental health issues, autoimmune diseases, and infections.

JAK inhibitors for alopecia areata are linked to minor side effects like headache and acne, but not to an increased risk of serious adverse events.

The EQ-5D-5L tool may not accurately measure the impact of alopecia areata on patients' lives.

The combination of laser and topical steroids is more effective for treating alopecia areata than topical steroids alone.

Guidelines suggest various treatments for alopecia areata, but leaving it untreated is also an option as 80% cases may recover on their own.

Ruxolitinib effectively regrows hair in most patients with severe hair loss.

Skin grafts on mice can cause an immune response leading to hair loss, useful for studying human hair loss conditions.

Alopecia areata significantly lowers the quality of life, especially in emotional and mental health aspects.

No single treatment is consistently effective for alopecia areata, and more research is needed.

People with alopecia areata often have other health issues like skin diseases, metabolic syndrome, stomach infections, lupus, anemia, thyroid problems, mental health issues, vitamin D deficiency, and hearing and eye problems.

Alopecia areata treatment varies, with no optimal method established yet.

Cancer patients treated with immune checkpoint inhibitors may develop alopecia, but some hair regrowth is possible with treatment.

Animal models have helped understand hair loss from alopecia areata and find new treatments.

Baricitinib is effective and safe for treating severe alopecia areata.

Lymphocytes, especially CD8+ T cells, play a key role in causing alopecia areata, and targeting them may lead to new treatments.

Despite progress in treatment, the exact cause of Alopecia areata is still unknown.

Intralesional triamcinolone acetonide is the most effective treatment for localized alopecia areata.

Apremilast was not effective in treating moderate-to-severe alopecia areata.

The document suggests using standardized methods to track and measure hair loss in alopecia areata, including patient self-assessment and a 50% improvement in specific scores as a treatment goal.

A woman's hair loss during treatment with specific hepatitis C drugs grew back after stopping the medication.

Older age at onset of alopecia areata leads to less severe and shorter episodes, with most patients experiencing significant hair regrowth.

Diphencyprone helped most patients with alopecia areata regrow some hair.

Korean Red Ginseng may help improve hair regrowth when used with corticosteroid injections for Alopecia Areata.

Two transplant patients on cyclosporine unexpectedly developed hair loss.

Early stage bald spots are linked to skin inflammation and damage to the upper part of the hair follicle.

Late-onset alopecia areata in Taiwanese patients is more common in women, usually starts at age 57, often involves less than 10% hair loss, and may have a minimal link to thyroid issues.

The research suggests that autophagy-related genes might play a role in causing alopecia areata.

Minoxidil effectively and safely treats patchy hair loss, but more research needed.